Teva Pharmaceutical Industries Ltd. and Celltrion Inc. will launch Truxima (rituximab-abbs), the first biosimilar version of Roche's blockbuster lymphoma drug Rituxan (rituximab) in the US, on 11 November. It marks the first US biosimilar launch for Teva, a generic powerhouse that nonetheless fell behind rivals in the race to bring the first wave of biosimilars to market.
The wholesale acquisition cost (WAC) for Truxima will be 10% lower than branded Rituxan, Teva said in announcing the launch...







